Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Habermann

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
The Oncologist|March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced CancersAnthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.
Blood|November 26, 2014
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphomaMuhammad A Mir, Matthew J Maurer, Steven C Ziesmer, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 9, 2022
Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic ExperienceJustin J Kuhlman, Muhamad Alhaj Moustafa, Liuyan Jiang, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2025
The Role of Radiation Therapy in the Management of Gray Zone LymphomaOmran Saifi, Scott C Lester, Nadia Laack, et al.
Leukemia & Lymphoma|November 3, 2025
Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort studyNadia Toumeh, Melissa Larson, Brianna Negaard, et al.
Leukemia|October 14, 2018
Primary systemic amyloidosis in patients with Waldenström macroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
British Journal of Haematology|October 26, 2023
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximabColleen A Ramsower, Allison Rosenthal, Ryan S Robetorye, et al.
Blood|August 23, 2003
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphomaKerry J Savage, Stefano Monti, Jeffery L Kutok, et al.
British Journal of Haematology|August 31, 2019
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomesJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Oncologist|March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced CancersAnthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.
Blood|November 26, 2014
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphomaMuhammad A Mir, Matthew J Maurer, Steven C Ziesmer, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 9, 2022
Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic ExperienceJustin J Kuhlman, Muhamad Alhaj Moustafa, Liuyan Jiang, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2025
The Role of Radiation Therapy in the Management of Gray Zone LymphomaOmran Saifi, Scott C Lester, Nadia Laack, et al.
Leukemia & Lymphoma|November 3, 2025
Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort studyNadia Toumeh, Melissa Larson, Brianna Negaard, et al.
Leukemia|October 14, 2018
Primary systemic amyloidosis in patients with Waldenström macroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
British Journal of Haematology|October 26, 2023
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximabColleen A Ramsower, Allison Rosenthal, Ryan S Robetorye, et al.
Blood|August 23, 2003
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphomaKerry J Savage, Stefano Monti, Jeffery L Kutok, et al.
British Journal of Haematology|August 31, 2019
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomesJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Pageof 4